Titre
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
McNamara, M.G.
Auteure/Auteur
Bridgewater, J.
Auteure/Auteur
Goyal, L.
Auteure/Auteur
Jacobs, T.
Auteure/Auteur
Wagner, A.D.
Auteure/Auteur
Goldstein, D.
Auteure/Auteur
Shroff, R.
Auteure/Auteur
Moehler, M.
Auteure/Auteur
Lowery, M.
Auteure/Auteur
Bekaii-Saab, T.
Auteure/Auteur
Kelley, R.K.
Auteure/Auteur
Furuse, J.
Auteure/Auteur
Rimassa, L.
Auteure/Auteur
Morizane, C.
Auteure/Auteur
Lamarca, A.
Auteure/Auteur
Hubner, R.
Auteure/Auteur
Knox, J.
Auteure/Auteur
Valle, J.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2044-6055
Statut éditorial
Publié
Date de publication
2022-10-26
Volume
12
Numéro
10
Première page
e064954
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Female physicians in medicine are increasing, but disparities in female authorship exist. The aim of this study was to characterise factors associated with female first (FF) and female senior (SF) authorship in later phase systemic oncological clinical trials in biliary tract cancer (BTC) and identify any changes over time.
Embase/Medline identified trial publications in BTC (2000-2020) were included. χ <sup>2</sup> tests and log regression were used (assessed factors associated with FF and SF authorship, including changes over time (STATA V.16)).
FF and SF authorship in later phase systemic oncological clinical trials in BTC.
Any changes over time?
Of 501 publications, 163 met inclusion criteria. The median percentage of female author representation in publications was 25%; there were no female authors in 13% of publications. Geographic location of the home institution of the first and senior authors was Asia (42%/42%), Europe (29%/29%), USA (24%/22%) and other (4%/6%), respectively. Overall, FF and SF author representation was 20% and 10%, respectively. The median position of the first female author was second in all the publication author lists. The phase of trial, journal-impact factor, industry funding or whether the study met its primary endpoint did not impact FF/SF author representation. More SF authors had home institutions in 'other' geographic locations (40% in 10 trials) (p=0.02) versus Asia (6%), Europe (8%) and USA (14%). There were no significant changes in FF/SF representation over time (p=0.61 and p=0.33 respectively).
FF and SF author representation in later phase systemic clinical trial publications in BTC is low and has not changed significantly over time. The underlying reasons for this imbalance need to be better understood and addressed.
Embase/Medline identified trial publications in BTC (2000-2020) were included. χ <sup>2</sup> tests and log regression were used (assessed factors associated with FF and SF authorship, including changes over time (STATA V.16)).
FF and SF authorship in later phase systemic oncological clinical trials in BTC.
Any changes over time?
Of 501 publications, 163 met inclusion criteria. The median percentage of female author representation in publications was 25%; there were no female authors in 13% of publications. Geographic location of the home institution of the first and senior authors was Asia (42%/42%), Europe (29%/29%), USA (24%/22%) and other (4%/6%), respectively. Overall, FF and SF author representation was 20% and 10%, respectively. The median position of the first female author was second in all the publication author lists. The phase of trial, journal-impact factor, industry funding or whether the study met its primary endpoint did not impact FF/SF author representation. More SF authors had home institutions in 'other' geographic locations (40% in 10 trials) (p=0.02) versus Asia (6%), Europe (8%) and USA (14%). There were no significant changes in FF/SF representation over time (p=0.61 and p=0.33 respectively).
FF and SF author representation in later phase systemic clinical trial publications in BTC is low and has not changed significantly over time. The underlying reasons for this imbalance need to be better understood and addressed.
PID Serval
serval:BIB_F26107797F0E
PMID
Open Access
Oui
Date de création
2022-11-09T09:52:17.936Z
Date de création dans IRIS
2025-05-21T06:38:37Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
36288834_BIB_F26107797F0E.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc/4.0
Taille
329.02 KB
Format
Adobe PDF
PID Serval
serval:BIB_F26107797F0E.P001
URN
urn:nbn:ch:serval-BIB_F26107797F0E7
Somme de contrôle
(MD5):371a639ecbadbc161e747fafca2e74ae